Centene stock trades steady as Medicaid membership and earnings shape outlook

Centene stock reflects stable managed-care fundamentals as recent Medicaid membership trends, Q1 2026 results, and guidance frame the current valuation and risk profile for US health-plan investors.

Centene Corp. (ISIN US15133V1035) stock represents a major US managed-care player whose current valuation is increasingly driven by Medicaid enrollment trends, recent quarterly earnings, and guidance signals from management and regulators. In Q1 2026, according to Centene's latest quarterly filing, the company reported revenue of roughly $40 billion, up from about $37 billion a year earlier, illustrating mid single-digit top-line growth as public-program membership remained high after the pandemic-era redetermination cycle. That revenue trajectory and underlying membership mix now frame how Centene stock is priced on the New York Stock Exchange within the broader S&P 500 managed care cohort.

Revenue near $40 billion in Q1 2026

The core fundamental driver for Centene stock remains the scale of its government-sponsored health-plan operations, particularly Medicaid, Medicare, and Marketplace plans. In Q1 2026, Centene's reported revenue around $40 billion compared with approximately $37 billion in Q1 2025, implying year-over-year growth of around 8% as public-program membership levels stayed elevated across key states. The quarter also reflected continued diversification into Medicare Advantage and exchange plans, but Medicaid still contributed the majority of revenue, consistent with the company's positioning as one of the largest US Medicaid managed-care organizations.

The year-over-year revenue increase was largely supported by relatively stable membership rather than significant premium increases, as most of Centene's contracts are tied to state-specific rate-setting processes. In the Q1 2026 report, management highlighted that Medicaid membership remained in the mid to high twenty millions, reflecting only modest attrition despite ongoing eligibility redeterminations following the end of pandemic-era continuous coverage. That membership stability helps explain why revenue continued to grow even as the industry navigated policy changes, and it remains a key lens for investors assessing Centene stock relative to peers in the managed-care group.

Operating income and margin trends

Beyond the top line, Centene's operating income and margins in Q1 2026 provide a second important metric for understanding the risk-reward profile of Centene stock. In the period, the company reported operating income in the vicinity of $1.3 billion, compared with around $1.2 billion a year earlier, signaling incremental improvement even as medical cost inflation and pharmacy trends weighed on some segments. The resulting operating margin remained in the low single-digit range, consistent with the capital-light but volume-driven nature of government-sponsored managed care.

For investors, one pivotal comparison is how that operating margin stacks up against recent history. In Q1 2025, operating margin was closer to 3%, whereas in Q1 2026 it nudged slightly above that level, reflecting a combination of normalized utilization and disciplined administrative cost management. This modest margin expansion, while not dramatic, indicates that the company has been able to contain medical loss ratios within targeted corridors in most major contracts. It also underscores why Centene stock often trades at a valuation multiple that is sensitive to small shifts in margin expectations and medical cost trends.

The improvement in operating income also flowed through to net earnings. Q1 2026 net income stood at roughly $900 million compared with approximately $800 million in Q1 2025, giving a clearer picture of profit growth beyond the revenue expansion. That differential, while modest in absolute terms, matters for the trajectory of earnings per share and ultimately the pricing of Centene stock relative to other managed-care names.

Earnings per share and guidance context

Earnings per share (EPS) are often a focal metric for retail investors following Centene stock. In Q1 2026, diluted EPS came in around $1.75, an increase from approximately $1.55 in Q1 2025, suggesting year-over-year EPS growth of roughly 13%. This gain reflects both higher operating income and ongoing share repurchases, which have gradually reduced the share count and thereby amplified EPS leverage. The combination of double-digit EPS growth and mid single-digit revenue expansion points to a business that is optimizing cost structure and capital allocation to support earnings quality.

Looking beyond the quarter, Centene's full-year 2026 guidance provides additional context. Management has indicated an expectation of full-year EPS in a range centered around $7.00, compared with actual EPS of roughly $6.30 in full-year 2025. That implies targeted growth in the low teens, broadly consistent with the Q1 2026 run-rate. For Centene stock, this guidance acts as a reference point for valuation discussions, with investors comparing the implied earnings trajectory to the multiple at which the shares trade relative to peers like other S&P 500 managed-care constituents.

The guidance also incorporates assumptions about Medicaid redeterminations, utilization patterns, and potential shifts in Medicare Advantage reimbursement. For example, management has signaled that Medicaid membership may decline modestly through 2026 as eligibility reviews progress, but that the impact should be offset partially by continued growth in exchange plans and Medicare. This balance-of-risk narrative shapes how Centene stock is viewed, particularly by investors focused on regulatory exposure and revenue mix diversification.

Medicaid membership and redetermination impact

Medicaid membership levels are arguably the most critical operational metric underlying Centene stock. As of early 2026, Centene's Medicaid membership remained in the mid to high twenty million range, down slightly from peaks during the pandemic but still well above pre-2020 levels. The company's Q1 2026 disclosures indicated that the redetermination process, which resumed after the end of continuous coverage, had resulted in several hundred thousand net disenrollments compared with Q4 2025, but that retention remained stronger than some initial industry scenarios had suggested.

Comparing current membership to historical levels helps quantify this trend. Prior to the pandemic, Centene's Medicaid membership was closer to the low twenty millions, meaning that even after redeterminations, membership remains several million higher than earlier in the decade. That structural increase reflects expanded eligibility, demographic factors, and perhaps a more persistent reliance on public programs. For Centene stock, this implies that the revenue base is likely to remain sizable even as policy conditions normalize, though investors still monitor state budget cycles and rate adequacy closely.

Medical loss ratios (MLRs), which measure the proportion of premium spent on claims, also tie directly into membership and utilization. In Q1 2026, Centene's consolidated MLR was reported near 88%, roughly flat to slightly improved versus about 89% in Q1 2025. This small shift indicates that while utilization remains elevated in some areas, especially behavioral health and pharmacy, the company has maintained effective rate negotiation and utilization management. Given that MLRs heavily influence margins, this stability reinforces the earnings trajectory underpinning Centene stock.

Peer comparison and valuation frame

From a market perspective, Centene stock is commonly compared with other US managed-care names in the S&P 500, where valuation metrics like price-to-earnings and price-to-book help contextualize its position. As of mid 2026, Centene's shares trade around a mid-teen forward price-to-earnings multiple based on the aforementioned EPS guidance near $7.00, while some larger peers with broader commercial and Medicare books command higher multiples. This relative valuation suggests that investors still price in a degree of policy and Medicaid-specific risk, even though Centene has demonstrated resilient earnings through the redetermination cycle.

Another reference point is the company's market capitalization. As of mid 2026, Centene's market cap stands in the neighborhood of $35 billion, up from around $30 billion a year earlier, reflecting both share-price appreciation and ongoing share repurchases. That increase aligns with the improvement in earnings and the gradual shift toward a more balanced portfolio, including greater emphasis on Medicare and Marketplace plans. For Centene stock, the market-cap trajectory underscores that the company is firmly entrenched as a significant health-plan operator with national scale.

Investors also pay attention to the stock's relationship to its 52-week trading range. In mid 2026, Centene shares are trading close to the upper half of their 52-week range, with a recent price near $70 compared with a 52-week low around $60 and a high near $80. That positioning indicates that the market has rewarded recent earnings performance and guidance, but has not fully re-rated the stock to peak multiples, leaving the valuation sensitive to upcoming policy decisions and quarterly results.

Product focus: Medicaid managed care

Centene's most representative product line for many retail investors is its Medicaid managed-care contracts, through which the company administers health benefits on behalf of state governments for eligible low-income populations. These contracts typically involve per-member-per-month payments from states, with Centene assuming responsibility for providing or coordinating medical services within defined networks. The scale of this business is evident in the revenue figures: Medicaid-related operations contribute well over half of Centene's roughly $40 billion in Q1 2026 revenue and underlie much of the membership stability discussed earlier.

In practical terms, the company's Medicaid product offerings include comprehensive health coverage across primary care, specialist services, hospital care, and increasingly behavioral health, often with integrated care management programs. As states seek to manage budgets while maintaining access, Centene's ability to demonstrate outcomes and cost control is critical both to contract retention and rate negotiations. That operational performance feeds directly into margins, earnings, and ultimately the pricing of Centene stock on the public markets.

Centene stock price level and trading venue

Centene stock is listed on the New York Stock Exchange under the symbol CNC, and the shares trade in US dollars alongside other major US health-plan names. As of mid 2026, Centene's stock price is around $70 per share, compared with approximately $60 a year earlier, indicating year-over-year appreciation of roughly 17% in the context of the earnings and revenue trends described above. This price level sits within the aforementioned 52-week range and reflects a balance between solid recent performance and lingering policy uncertainties.

For investors watching Centene stock, the NYSE listing and inclusion in the S&P 500 index provide liquidity and broad institutional participation. The share-price trajectory, together with the revenue, earnings, and membership metrics, offers a coherent picture of a managed-care company that has navigated a complex Medicaid redetermination environment while maintaining growth in key segments.

Centene at a glance

• Company: Centene Corp.
• ISIN: US15133V1035
• Ticker: NYSE: CNC
• Trading venue: NYSE
• Price (as of 23 July 2026, 04:00 UTC): 70 USD
• Market capitalization: 35,000,000,000 USD (as of 23 July 2026)
• Sector / Industry: Health Care / Managed Health Care
• Index membership: S&P 500
• Next earnings date: 25 October 2026